[EN] NOVEL UREA COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION<br/>[FR] NOUVEAUX COMPOSES A BASE D'UREE, COMPOSITIONS LES CONTENANT, ET PROCEDES D'UTILISATION ET DE PREPARATION DE CEUX-CI
申请人:VERSICOR INC
公开号:WO2001044178A1
公开(公告)日:2001-06-21
Novel hydroxamic acid compounds of Formula (I) are disclosed. These hydroxamates inhibit peptide deformylase (PDF), an enzyme present in prokaryotes and are therefore useful as antimicrobials and antibiotics. Methods of synthesis and use of the compounds are also disclosed.
This invention is directed to a compound of formula (I):
wherein R
1
, R
2
, R
3
, R
4
and L
1
are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).
HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS
申请人:WAGNER Michael
公开号:US20080167346A1
公开(公告)日:2008-07-10
The present invention relates to compounds of the formula I,
which exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses.
N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
申请人:Deciphera Pharmaceuticals, LLC
公开号:US09309224B2
公开(公告)日:2016-04-12
Described are compounds of Formula 1
which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
Constitution: a novel compound represented by general formula (1), wherein R¹ represents -OR³ (R³ being H or alkyl), -NR⁴R⁵ (R⁴ and R⁵ being each H, alkyl or alkoxy), -NHCH(R⁶)COR⁷ (R⁶ being H or alkyl, and R⁷ being alkyl), -NHCH(R⁶)COOR⁸(R⁸ being alkyl) or -NHCH(R⁶)CONR⁹R¹⁰ (R⁹ and R¹⁰ being each H or alkyl, or alternatively NR⁹R¹⁰ being a heterocyclic group as a whole); and R² represents H, alkyl or aralkyl. Effect: since the compound has an inhibitory activity type IV collagenase, it is useful as an inhibitor against vascularization, cancer infiltration or cancer metastasis.
构成:通式(1)代表的新型化合物,其中R¹代表-OR³(R³为H或烷基)、-NR⁴R⁵(R⁴和R⁵各自为H、烷基或烷氧基)、-NHCH(R⁶)COR⁷(R⁶为H或烷基、和 R⁷ 为烷基)、-NHCH(R⁶)COOR⁸(R⁸ 为烷基)或-NHCH(R⁶)CONR⁹R¹⁰(R⁹ 和 R¹⁰ 分别为 H 或烷基,或者 NR⁹R¹⁰ 整体为杂环基团);R² 代表 H、烷基或芳烷基。效果:由于该化合物具有抑制 IV 型胶原酶的活性,因此可用作血管化、癌症浸润或癌症转移的抑制剂。